Among a cohort of 60 MM patients with no history of SARS-CoV-2 infection, four were infected after one dose (n = 2) or two doses (n = 2) of BNT162b2, and all of them were receiving anti-CD38 immunotherapy [40]. The gene discussed is CD38; the disease is Miyoshi myopathy.